{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-23-003950","form_type":"8-K","ticker":null,"cik":"0000910267","company_name":"TITAN PHARMACEUTICALS INC","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.755010+00:00","generated_at":"2026-06-14T07:05:38.691942+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Titan Pharmaceuticals receives Nasdaq extension to Oct 2, 2023 to regain compliance with $2.5M equity requirement","bullets":["Stockholders' equity reported at $1.363M, below Nasdaq's $2.5M minimum.","Nasdaq grants 180-day extension to October 2, 2023 to demonstrate compliance.","Company submitted a compliance plan on May 22, 2023.","Failure to comply by Oct 2 or upon filing 2023 10-K may lead to delisting.","Delisting would reduce liquidity, market price, and access to financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-23-003950","json":"https://secwatch.observer/filing/0001829126-23-003950.json","markdown":"https://secwatch.observer/filing/0001829126-23-003950.md","text":"https://secwatch.observer/filing/0001829126-23-003950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910267/000182912623003950/0001829126-23-003950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910267/000182912623003950/titanpharma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:05:38.691942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61af1c5937f8e6f6cd05c317aae4c24e32a24ed7","claim":"TITAN PHARMACEUTICALS INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"that a listed company’s stockholders’ equity be at least $2,500,000 (the “Stockholders’ Equity Requirement”). In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy the Stockholders’ Equity Requirement. The Company submitted a plan to regain compliance with the Stockholders’ Equity Requirement","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/910267/000182912623003950/0001829126-23-003950-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}